Citations (62)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Siang Fei Yeoh, Tae Jin Lee, Ka Lip Chew, Stephen Lin, Dennis Yeo & Sajita Setia. (2018) Echinocandins for management of invasive candidiasis in patients with liver disease and liver transplantation. Infection and Drug Resistance 11, pages 805-819.
Read now
Read now
Prasanna Raju Y, Hyndavi N, Harini Chowdary V, Rajesh S Nair, Jamal Basha D & Tejeswari N. (2017) In vitro assessment of non-irritant microemulsified voriconazole hydrogel system. Artificial Cells, Nanomedicine, and Biotechnology 45:8, pages 1539-1547.
Read now
Read now
Georg Maschmeyer, Thierry Calandra, Nina Singh, Joseph Wiley & John Perfect. (2009) Invasive mould infections: a multi-disciplinary update. Medical Mycology 47:6, pages 571-583.
Read now
Read now
Kazuo Tamura, Akio Urabe, Minoru Yoshida, Akihisa Kanamaru, Yoshihisa Kodera, Shinichiro Okamoto, Shigefumi Maesaki & Tohru Masaoka. (2009) Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders. Leukemia & Lymphoma 50:1, pages 92-100.
Read now
Read now
Paul O Gubbins & Jarrett R Amsden. (2005) Drug–drug interactions of antifungal agents and implications for patient care. Expert Opinion on Pharmacotherapy 6:13, pages 2231-2243.
Read now
Read now
Jaroslav Sterba, Jaroslav Prochazka, Jiri Ventruba, Leos Kren, Dalibor Valik, Dagmar Burgetova, Peter Mudry, Jarmila Skotakova & Jan Blatny. (2005) SUCCESSFUL TREATMENT OF ASPERGILLUS BRAIN ABSCESS IN A CHILD WITH ACUTE LYMPHOBLASTIC LEUKEMIA AND LIVER FAILURE. Pediatric Hematology and Oncology 22:8, pages 649-655.
Read now
Read now
M. O'Doherty, M. Hannan & T. Fulcher. (2005) Voriconazole in the Treatment of Fungal Osteomyelitis of the Orbit in the Immunocompromised Host. Orbit 24:4, pages 285-289.
Read now
Read now
Articles from other publishers (55)
Tomas Di Mambro, Tania Vanzolini, Pierpaolo Bruscolini, Sergio Perez-Gaviro, Emanuele Marra, Giuseppe Roscilli, Marzia Bianchi, Alessandra Fraternale, Giuditta Fiorella Schiavano, Barbara Canonico & Mauro Magnani. (2021) A new humanized antibody is effective against pathogenic fungi in vitro. Scientific Reports 11:1.
Crossref
Crossref
Emese Tolnai, Gábor Fidler, Róbert Szász, László Rejtő, Kingsley Okechukwu Nwozor, Sándor Biró & Melinda Paholcsek. (2020) Free circulating mircoRNAs support the diagnosis of invasive aspergillosis in patients with hematologic malignancies and neutropenia. Scientific Reports 10:1.
Crossref
Crossref
Yiqi Li, Chao Zhu, Hui Wu, Hongchun Pan & Hong Liu. (2020) Kolliphor® HS 15-cyclodextrin Complex for the Delivery of Voriconazole: Preparation, Characterization, and Antifungal Activity. Current Drug Metabolism 21:5, pages 379-389.
Crossref
Crossref
Eman Ali Saeed Alghamdi, Abdulmalik Yahya Al Qahtani, Mazen M. Sinjab & Khalid Mohammed AlyahyaEman Ali Saeed Alghamdi, Abdulmalik Yahya Al Qahtani, Mazen M. Sinjab & Khalid Mohammed Alyahya. 2020. Extemporaneous Ophthalmic Preparations. Extemporaneous Ophthalmic Preparations
25
59
.
Elda Righi. (2018) Management of bacterial and fungal infections in end stage liver disease and liver transplantation: Current options and future directions. World Journal of Gastroenterology 24:38, pages 4311-4329.
Crossref
Crossref
P. Fonda-Pascual, P. Fernández-González, O.M. Moreno-Arrones & L. Miguel-Gómez. (2018) Pustular Secondary Cutaneous Aspergillosis in an Immunosuppressed Patient. Actas Dermo-Sifiliográficas (English Edition) 109:3, pages 287-290.
Crossref
Crossref
P. Fonda-Pascual, P. Fernández-González, O.M. Moreno-Arrones & L. Miguel-Gómez. (2018) Aspergilosis cutánea secundaria pustulosa en paciente inmunosuprimido. Actas Dermo-Sifiliográficas 109:3, pages 287-290.
Crossref
Crossref
Harshad Devarbhavi, Herbert L. Bonkovsky, Mark Russo & Naga Chalasani. 2018. Zakim and Boyer's Hepatology. Zakim and Boyer's Hepatology
844
890.e17
.
Jeremy R. DeGrado, James F. Gilmore, Benjamin Hohlfelder, Craig A. Stevens & Steven Gabardi. 2018. Core Concepts in Acute Kidney Injury. Core Concepts in Acute Kidney Injury
343
361
.
Romuald Bellmann & Piotr Smuszkiewicz. (2017) Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection 45:6, pages 737-779.
Crossref
Crossref
. 2016. Meyler's Side Effects of Drugs. Meyler's Side Effects of Drugs
504
521
.
Sumit Arora, Mehra Haghi, Ching-Yee Loo, Daniela Traini, Paul M. Young & Sanyog Jain. (2015) Development of an Inhaled Controlled Release Voriconazole Dry Powder Formulation for the Treatment of Respiratory Fungal Infection. Molecular Pharmaceutics 12:6, pages 2001-2009.
Crossref
Crossref
Felix Stader, Gudrun Wuerthwein, Andreas H. Groll, Joerg-Janne Vehreschild, Oliver A. Cornely & Georg Hempel. (2014) Physiology-Based Pharmacokinetics of Caspofungin for Adults and Paediatrics. Pharmaceutical Research 32:6, pages 2029-2037.
Crossref
Crossref
John E. EdwardsJr.Jr.. 2015. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases
2879
2894.e3
.
M Bosilkovska, C F Samer, J Déglon, M Rebsamen, C Staub, P Dayer, B Walder, J A Desmeules & Y Daali. (2014) Geneva Cocktail for Cytochrome P450 and P-Glycoprotein Activity Assessment Using Dried Blood Spots. Clinical Pharmacology & Therapeutics 96:3, pages 349-359.
Crossref
Crossref
Gudrun Würthwein, Oliver A. Cornely, Mirjam N. Trame, Janne J. Vehreschild, Maria J. G. T. Vehreschild, Fedja Farowski, Carsten Müller, Joachim Boos, Georg Hempel, Michael Hallek & Andreas H. Groll. (2013) Population Pharmacokinetics of Escalating Doses of Caspofungin in a Phase II Study of Patients with Invasive Aspergillosis. Antimicrobial Agents and Chemotherapy 57:4, pages 1664-1671.
Crossref
Crossref
Herbert L. Bonkovsky, Dean P. Jones, Mark W. Russo & Steven I. Shedlofsky. 2012. Zakim and Boyer's Hepatology. Zakim and Boyer's Hepatology
417
461
.
O. A. Cornely, J. J. Vehreschild, M. J. G. T. Vehreschild, G. Würthwein, D. Arenz, S. Schwartz, C. P. Heussel, G. Silling, M. Mahne, J. Franklin, U. Harnischmacher, A. Wilkens, F. Farowski, M. Karthaus, T. Lehrnbecher, A. J. Ullmann, M. Hallek & A. H. Groll. (2011) Phase II Dose Escalation Study of Caspofungin for Invasive Aspergillosis. Antimicrobial Agents and Chemotherapy 55:12, pages 5798-5803.
Crossref
Crossref
Maria Luisa Mangoni & Yechiel Shai. (2011) Short native antimicrobial peptides and engineered ultrashort lipopeptides: similarities and differences in cell specificities and modes of action. Cellular and Molecular Life Sciences 68:13, pages 2267-2280.
Crossref
Crossref
R Herbrecht, J Maertens, L Baila, M Aoun, W Heinz, R Martino, S Schwartz, A J Ullmann, L Meert, M Paesmans, O Marchetti, H Akan, L Ameye, M Shivaprakash & C Viscoli. (2010) Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study. Bone Marrow Transplantation 45:7, pages 1227-1233.
Crossref
Crossref
Daoud Al-Badriyeh, Jian Li, Kay Stewart, David C. M. Kong, Lok Leung, Geoffrey E. Davies & Robert Fullinfaw. (2009) Stability of extemporaneously prepared voriconazole ophthalmic solution. American Journal of Health-System Pharmacy 66:16, pages 1478-1483.
Crossref
Crossref
Bijoy P. Mathew & Mahendra Nath. (2009) Recent Approaches to Antifungal Therapy for Invasive Mycoses. ChemMedChem 4:3, pages 310-323.
Crossref
Crossref
Arik Makovitzki, Jonathan Baram & Yechiel Shai. (2008)
Antimicrobial Lipopolypeptides Composed of Palmitoyl Di- and Tricationic Peptides:
In Vitro
and
in Vivo
Activities, Self-Assembly to Nanostructures, and a Plausible Mode of Action
. Biochemistry 47:40, pages 10630-10636.
Crossref
Crossref
J.-M. Constantin, L. Roszyk, R. Guerin, F. Bannier, C. Chartier, S. Perbet, E. Futier, S. Cayot-Constantin, V. Sapin & J.-E. Bazin. (2008) Tolérance de la caspofongine chez les patients de réanimation : étude prospective. Annales Françaises d'Anesthésie et de Réanimation 27:10, pages 819-824.
Crossref
Crossref
Zlate Stojanoski, Aleksandra Pivkova, Sonja Genadieva-Stavrik, Lidija Cevreska, Milena Petrovska & Borche Georgievski. (2008) Antifungal Prophylaxis In Hematopoietic Stem Cell Transplant Recipients. Macedonian Journal of Medical Sciences 1:1, pages 50-58.
Crossref
Crossref
Loralie J. Langman & Felix Boakye-Agyeman. (2007) Measurement of voriconazole in serum and plasma. Clinical Biochemistry 40:18, pages 1378-1385.
Crossref
Crossref
David S. Perlin. (2007) Resistance to echinocandin-class antifungal drugs. Drug Resistance Updates 10:3, pages 121-130.
Crossref
Crossref
Donald A. Novak, Gregory Y. Lauwers & Richard L. Kradin. 2009. Liver Disease in Children. Liver Disease in Children
871
896
.
James A. Dowell, Martin Stogniew, David Krause, Timothy Henkel & Bharat Damle. (2007) Lack of Pharmacokinetic Interaction Between Anidulafungin and Tacrolimus. The Journal of Clinical Pharmacology 47:3, pages 305-314.
Crossref
Crossref
Matthew E. Falagas, Fotinie Ntziora, Gregoria I. Betsi & George Samonis. (2007) Caspofungin for the treatment of fungal infections: a systematic review of randomized controlled trials. International Journal of Antimicrobial Agents 29:2, pages 136-143.
Crossref
Crossref
Inés Contreras, Carolina Arruabarrena & Marta S. Figueroa. (2007) TREATMENT OF BILATERAL CANDIDAL ENDOPHTHALMITIS WITH INTRAVENOUS CASPOFUNGIN. RETINAL Cases & Brief Reports 1:3, pages 175-177.
Crossref
Crossref
Thomas J. Walsh, Issam Raad, Thomas F. Patterson, Pranatharthi Chandrasekar, Gerald R. Donowitz, Richard Graybill, Reginald E. Greene, Ray Hachem, Susan Hadley, Raoul Herbrecht, Amelia Langston, Arnold Louie, Patricia Ribaud, Brahm H. Segal, David A. Stevens, Jo‐Anne H. van Burik, Charles S. White, Gavin Corcoran, Jagadish Gogate, Gopal Krishna, Lisa Pedicone, Catherine Hardalo & John R. Perfect. (2007) Treatment of Invasive Aspergillosis with Posaconazole in Patients Who Are Refractory to or Intolerant of Conventional Therapy: An Externally Controlled Trial. Clinical Infectious Diseases 44:1, pages 2-12.
Crossref
Crossref
Juan Sainz, Eva Pérez, Laila Hassan, Antonio Moratalla, Antonio Romero, María Dolores Collado & Manuel Jurado. (2007) Variable Number of Tandem Repeats of TNF Receptor Type 2 Promoter as Genetic Biomarker of Susceptibility to Develop Invasive Pulmonary Aspergillosis. Human Immunology 68:1, pages 41-50.
Crossref
Crossref
I. I. Raad, J. R. Graybill, A. B. Bustamante, O. A. Cornely, V. Gaona-Flores, C. Afif, D. R. Graham, R. N. Greenberg, S. Hadley, A. Langston, R. Negroni, J. R. Perfect, P. Pitisuttithum, A. Restrepo, G. Schiller, L. Pedicone & A. J. Ullmann. (2006) Safety of Long-Term Oral Posaconazole Use in the Treatment of Refractory Invasive Fungal Infections. Clinical Infectious Diseases 42:12, pages 1726-1734.
Crossref
Crossref
M Braun-Falco & J Ring. (2006) Nodular erythema as early sign of systemic aspergillosis. Journal of the European Academy of Dermatology and Venereology 20:5, pages 610-612.
Crossref
Crossref
Herbert L. Bonkovsky, Dean P. Jones, Douglas R. LaBrecque & Steven I. Shedlofsky. 2006. Zakim and Boyer's Hepatology. Zakim and Boyer's Hepatology
503
550
.
. 2006. Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions. Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions
3688
3691
.
Mary F. Hebert, David K. Blough, Robert W. Townsend, Mark Allison, Donald Buell, James Keirns & Ihor Bekersky. (2005) Concomitant Tacrolimus and Micafungin Pharmacokinetics in Healthy Volunteers. The Journal of Clinical Pharmacology 45:9, pages 1018-1024.
Crossref
Crossref
Anna Candoni, Rosalba Mestroni, Daniela Damiani, Mario Tiribelli, Angela Michelutti, Federico Silvestri, Maurizio Castelli, Pierluigi Viale & Renato Fanin. (2005) Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies. European Journal of Haematology 75:3, pages 227-233.
Crossref
Crossref
Peter A. Warn, Andrew Sharp, Graham Morrissey & David W. Denning. (2005) Activity of aminocandin (IP960) compared with amphotericin B and fluconazole in a neutropenic murine model of disseminated infection caused by a fluconazole-resistant strain of Candida tropicalis. Journal of Antimicrobial Chemotherapy 56:3, pages 590-593.
Crossref
Crossref
Kevin B. Laupland, Daniel B. Gregson, Deirdre L. Church, Terry Ross & Sameer Elsayed. (2005) Invasive Candida species infections: a 5 year population-based assessment. Journal of Antimicrobial Chemotherapy 56:3, pages 532-537.
Crossref
Crossref
Misty T. Sharp & Thomas D. Horn. (2005) Pseudoporphyria induced by voriconazole. Journal of the American Academy of Dermatology 53:2, pages 341-345.
Crossref
Crossref
Lana Gerzenshtein, Shilpa M Patel, Kimberly K Scarsi, Michael J Postelnick & John P Flaherty. (2005)
Breakthrough
Candida
Infections in Patients Receiving Voriconazole
. Annals of Pharmacotherapy 39:7-8, pages 1342-1345.
Crossref
Crossref
R Fanci, S Guidi, M Bonolis & A Bosi. (2005) Candida krusei fungemia in an unrelated allogeneic hematopoietic stem cell transplant patient successfully treated with Caspofungin. Bone Marrow Transplantation 35:12, pages 1215-1216.
Crossref
Crossref
Steven Gabardi & Stuart Abramson. (2005) Drug Dosing in Chronic Kidney Disease. Medical Clinics of North America 89:3, pages 649-687.
Crossref
Crossref
Andrew J. Racette, Henry H. RoenigkJr.Jr., Ronald Hansen, Deborah Mendelson & Anngela Park. (2005) Photoaging and phototoxicity from long-term voriconazole treatment in a 15-year-old girl. Journal of the American Academy of Dermatology 52:5, pages S81-S85.
Crossref
Crossref
R. Courtney, A. Sansone, W. Smith, T. Marbury, P. Statkevich, M. Martinho, M. Laughlin & S. Swan. (2005) Posaconazole Pharmacokinetics, Safety, and Tolerability in Subjects With Varying Degrees of Chronic Renal Disease. The Journal of Clinical Pharmacology 45:2, pages 185-192.
Crossref
Crossref
Robert L. PageIIIIGeraldine G. MillerJoAnn Lindenfeld. (2005) Drug Therapy in the Heart Transplant Recipient. Circulation 111:2, pages 230-239.
Crossref
Crossref
Juan C. Gea-Banacloche, Steven M. Opal, James Jorgensen, Joseph A. Carcillo, Kent A. Sepkowitz & Catherine Cordonnier. (2004) Sepsis associated with immunosuppressive medications: An evidence-based review. Critical Care Medicine 32:Supplement, pages S578-S590.
Crossref
Crossref
Shakhsanam E. Aliyeva, Andrew J. Ullmann, Ulrike B. Kottler, Martine Frising & Oliver Schwenn. (2004) Histological examination of an eye with endogenous Aspergillus endophthalmitis treated with oral voriconazole: a case report. Graefe's Archive for Clinical and Experimental Ophthalmology 242:10, pages 887-891.
Crossref
Crossref
Simone Cesaro, Tiziana Toffolutti, Chiara Messina, Elisabetta Calore, Rita Alaggio, Riccardo Cusinato, Marta Pillon & Luigi Zanesco. (2004) Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis. European Journal of Haematology 73:1, pages 50-55.
Crossref
Crossref
O. Leroy & F. Ajana. (2004) Caspofungine, place dans les stratégies thérapeutiques antifongiques. Antibiotiques 6:2, pages 132-143.
Crossref
Crossref
John R Wingard & Helen Leather. (2004) A new era of antifungal therapy. Biology of Blood and Marrow Transplantation 10:2, pages 73-90.
Crossref
Crossref
Rowena K. Richter, Daniel E. Mickus, Scott D. Rychnovsky & Tadeusz F. Molinski. (2004) Differential modulation of the antifungal activity of amphotericin B by natural and ent-cholesterol. Bioorganic & Medicinal Chemistry Letters 14:1, pages 115-118.
Crossref
Crossref
. (2003) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 13:1, pages 49-64.
Crossref
Crossref